Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CATALYST BIOSCIENCES INC

SummaryNewsRatingsCalendarCompany 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about CATALYST BIOSCIENCES INC
01/25Catalyst Biosciences Secures Rare Pediatric Disease Designation for Immune Defect Drug
MT
01/25Catalyst Biosciences Shares Rise Premarket After Key FDA Designation
DJ
01/25CATALYST BIOSCIENCES : Receives Rare Pediatric Disease Designation for CB 4332 for the Tre..
PU
01/25Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Tr..
AQ
01/25Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Tr..
CI
01/12CATALYST BIOSCIENCES : Investor presentation 5.9 MB
PU
2021Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Con..
AQ
2021CATALYST BIOSCIENCES : Investor presentation 4.7 MB
PU
2021Catalyst Biosciences Announces Change in Corporate Strategy
AQ
2021Catalyst Biosciences to Seek Buyer for its Hemophilia Assets
CI
2021Piper Sandler Adjusts Price Target on Catalyst Biosciences to $4 From $16, Reiterates O..
MT
2021JonesTrading Downgrades Catalyst Biosciences to Hold From Buy
MT
2021Raymond James Downgrades Catalyst Biosciences to Market Perform From Outperform
MT
2021Catalyst Biosciences to Stop Hemophilia Drug Candidate Development; Loss Widens in Q3 a..
MT
2021Catalyst Biosciences Announces Change in Corporate Strategy Reports Third Quarter 2021 ..
PU
More most relevant news
All news about CATALYST BIOSCIENCES INC
01/25Catalyst Biosciences Secures Rare Pediatric Disease Designation for Immune Defect Drug
MT
01/25Catalyst Biosciences Shares Rise Premarket After Key FDA Designation
DJ
01/25CATALYST BIOSCIENCES : Receives Rare Pediatric Disease Designation for CB 4332 for the Tre..
PU
01/25CATALYST BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/25Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Tr..
AQ
01/25Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Tr..
CI
01/12CATALYST BIOSCIENCES : Investor presentation 5.9 MB
PU
01/12CATALYST BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
2021Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Con..
AQ
2021CATALYST BIOSCIENCES : Investor presentation 4.7 MB
PU
More news
News in other languages on CATALYST BIOSCIENCES INC
01/25Catalyst Biosciences obtient la désignation de maladie pédiatrique rare pour un médicam..
01/25Catalyst Biosciences reçoit la désignation de maladie pédiatrique rare pour le CB 4332 ..
2021Les actions du secteur de la santé se renforcent en fin de journée de vendredi
2021Les actions du secteur de la santé affichent des gains modestes cet après-midi
2021Catalyst Biosciences va arrêter le développement d'un médicament candidat contre l'hémo..
2021Catalyst Biosciences obtient la désignation de médicament orphelin de la FDA pour le tr..
2021Catalyst Biosciences nomme Grant Blouse au poste de directeur scientifique.
2021Catalyst Biosciences reçoit la désignation Fast Track de la FDA pour Marzeptacog Alfa
2021Catalyst Biosciences administre une première dose à un patient dans le cadre d'une étud..
2021Catalyst Biosciences administre une dose à un premier patient dans le cadre de l'étude ..
More news
Analyst Recommendations on CATALYST BIOSCIENCES INC
2021Piper Sandler Adjusts Price Target on Catalyst Biosciences to $4 From $16, Reiterates O..
MT
2021JonesTrading Downgrades Catalyst Biosciences to Hold From Buy
MT
2021Raymond James Downgrades Catalyst Biosciences to Market Perform From Outperform
MT
2021CATALYST BIOSCIENCES : Piper Sandler Starts Catalyst Biosciences at Overweight With $15 Pr..
MT
2021CATALYST BIOSCIENCES : Raymond James Adjusts Price Target on Catalyst Biosciences to $18 F..
MT
More recommendations
Press releases
01/25CATALYST BIOSCIENCES : Receives Rare Pediatric Disease Designation for CB 4332 for the Tre..
PU
01/25CATALYST BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/25Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Tr..
AQ
01/12CATALYST BIOSCIENCES : Investor presentation 5.9 MB
PU
01/12CATALYST BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
More press releases
Upcoming event on CATALYST BIOSCIENCES INC